Risks
4 risks
Risk Intelligence
Potential OAI outcome at FTO-3 facility
View Risks →
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Dr. Reddy's delivered a solid Q3 FY24 with INR 7,215 crore revenue (+7% YoY) and INR 1,379 crore PAT (+11% YoY), driven by US generics (up 7% to $401M) and Europe (up 8% to EUR 55M). EBITDA margin held at 29.3% despite SG&A investments. Management highlighted a pipeline of 26 meaningful US launches over FY25-26 and six biosimilars targeting first-to-market by FY30. India base business is expected to return to double-digit growth from FY25, supported by key brands growing 1.5x market. Risks include potential OAI outcome at FTO-3 facility (10 observations) and price erosion in US generics, though management noted stable pricing trends.
डॉ. रेड्डीज ने तीसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 7,215 करोड़ रुपये रही, जो पिछले साल से 7% ज्यादा है। मुनाफा 1,379 करोड़ रुपये रहा, जो 11% बढ़ा। अमेरिका में जेनेरिक दवाओं की बिक्री 7% बढ़कर 401 मिलियन डॉलर और यूरोप में 8% बढ़कर 55 मिलियन यूरो हुई। कंपनी ने अगले दो सालों में अमेरिका में 26 नई दवाएं लॉन्च करने की योजना बनाई है। भारत में कारोबार अगले साल से दो अंकों की दर से बढ़ने की उम्मीद है। जोखिमों में अमेरिकी नियामक की जांच और जेनेरिक दवाओं की कीमतों में गिरावट शामिल है, लेकिन कंपनी का कहना है कि कीमतें स्थिर हैं।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Generics Revenue
$401M
+7% YoY
North America generic sales grew 7% YoY, driven by market share expansion and new launches.
Europe Generics Revenue
EUR 55M
+8% YoY
European business grew 8% YoY, supported by new product launches and volume improvement.
India Business Revenue
INR 1,180 Cr
+5% YoY
India sales grew 5% YoY; management expects double-digit growth in coming quarters.
PSAI Revenue
$94M
+11% QoQ
PSAI segment grew 11% sequentially, with gross margin improving to ~22% from 13%.
What Changed vs Last Quarter
NEW
26 meaningful US launches over FY25-26
Approximately 26 products with potential sales >$10M each are expected to launch in the US over the next two years, subject to approvals.
NEW
Six biosimilars targeting first-to-market by FY30
Biosimilar pipeline includes six products aiming for first-to-market status, with first launch expected in early CY2027.
NEW
SG&A investments to continue at elevated levels
SG&A spend will remain higher in absolute terms as investments in brands and pipeline products continue, with revenue growth expected to provide operating leverage.
UPDATED
India business to deliver double-digit growth from FY25
Management expects India base business to return to double-digit growth in coming quarters, driven by key brands growing at 1.5x market rate.
DROPPED
25-30 product launches in US for FY2024
Company is on track to launch 25-30 products in the US this fiscal year, with 4 launched in Q2.
DROPPED
Biosimilar rituximab launch in US in early FY2025
Rituximab biosimilar submitted in April 2023; pre-approval inspection completed. Launch expected in early FY2025 if regulatory issues resolved.
DROPPED
SG&A as % of sales to remain around 28-29% for FY2024
CFO indicated SG&A as a percentage of sales will be in the 28-29% range for the full year, despite investments in digitalization and brands.
NEW RISK
Potential OAI outcome at FTO-3 facility
FDA issued Form 483 with 10 observations at FTO-3; management has responded but risk of OAI classification could impact approvals and reputation.
NEW RISK
Dependence on Revlimid for cash flows
Revlimid contribution remains meaningful; any unexpected decline could impact cash generation and ability to invest in pipeline.
NEW RISK
Supply chain disruptions from Red Sea crisis
Geopolitical tensions are causing sea route disruptions; management is building inventory but costs could rise if situation persists.
RISK GONE
FDA observations at Bachupally biologics facility
US FDA pre-approval inspection resulted in 9 observations. Management believes they are addressable but could delay biosimilar approvals if not resolved timely.
RISK GONE
India business growth trajectory uncertainty
Despite guidance for double-digit growth by year-end, India business has been range-bound for several quarters. Analyst questioned the timeline for material step-up.
Fast read
Guidance and risk preview
Management expects India base business to return to double-digit growth in coming quarters, driven by key brands growing at 1.5x market rate.
FDA issued Form 483 with 10 observations at FTO-3; management has responded but risk of OAI classification could impact approvals and reputation.
View Risks →